17,261 trials
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Forced Expiratory Volume in First Second (FEV1) Area Under Curve (AUC) 0-12h at Day 7 on Treatment — 0.128; 0.151; 0.183; 0.184 Liters
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 hr at Day 15 on Treatment. — 0.236; 0.260; 0.015 Liters
Asthma
Primary: PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1) — 35.0; 20.9; 33.2; 17.8 mg/ml
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Heart Failure
Primary: Diuretic Efficacy Index 1 for Sodium Excretion — 10.185; 12.122; 13.453; 12.858 mmol/mg
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Acute Myocardial Infarction
Primary: Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention — 100; 100 Percent diameter…
Neuroendocrine Tumor · Islet Cell Tumor
Primary: Percentage of Participants With Progression Free Survival (PFS) at 12 Months — 66 percentage of participants
Epilepsy
Primary: Change in the Number of Seizure Days With Absence Seizures From the Baseline Phase to the Maintenance Phase — -0.37 number of seizure days
Renal Cell Carcinoma
Primary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Diabetic Macular Edema
Primary: Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS)…